In many cancers, SERPINB3/SCCA (the ELISA-based clinical assay used to measure circulating SERPINB3 is still referred to as “SCCA”) is highly expressed in tumors or in the circulation of patients with cancer, including cervical, head and neck, lung, breast, and esophageal cancers, and is often associated with poor prognosis and treatment outcomes and disease recurrence (11–15). This evidence concerns the gene SERPINB3 and esophageal cancer.